The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. (Q50506558)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Olivier Hermine

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Didier Bouscary

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jerome Tamburini

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Nicolas Chapuis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alexandre Puissant

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Thiago Trovati Maciel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Olivier Hérault

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ivan C Moura

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Patrick Auberger

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Norbert Ifrah

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

A S Green

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

N Jacque

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Vignon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Park

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Guichard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

A Fricot

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

F Dreyfus

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

D Bonnet

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Lacombe

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

P Mayeux

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

6 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1195-1202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22143671%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.339

17 January 2020

exact match

0 references

cites work

Functional proteomics to dissect tyrosine kinase signalling pathways in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

mTOR and cancer: insights into a complex relationship

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Ribosomal protein S6 phosphorylation: from protein synthesis to cell size.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Regulation of translation initiation by FRAP/mTOR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

eIF-4E expression and its role in malignancies and metastases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Targeting translation in acute myeloid leukemia: a new paradigm for therapy?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Taking aim at protein translation in AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Translational control in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Targeting autophagy to fight hematopoietic malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Autophagy as a cell death and tumor suppressor mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Astrocyte elevated gene-1 induces protective autophagy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.339

7 January 2021